PRKDC and malignant glioma: Our previous studies have shown that MYT1L is elevated in 46.9% of malignant glioma tissues (n = 32) and may contribute to the progression of glioblastoma through the interaction with the DNA-dependent protein kinase (DNA-PK) [29], highlighting a novel modulatory role of DNA-PK in MYT1L-dependent transcription.